Evariste

Our very own Principal Scientist, Daniel Miller is the featured expert in EditCo Bio’s upcoming webinar: AI-driven identification and validation of novel synthetic lethal gene pairs.  The webinar will discuss how Evariste leverages AI to accelerate drug discovery, utilizing EditCo's CRISPR Express Cell Pools and Arctoris' Ulysses® to drive rapid target validation. Topics covered include: 🔬 Synthetic lethality (SL) as a promising, untapped oncology strategy, with currently limited actionable targets. 🔍 How Evariste uses Frobenius Target to identify novel SL gene pairs and validates them using high-throughput CRISPR editing and robotic cell biology assays. 💡 Case study on a novel SL pair involving the oncology target FAK, showcasing the platform’s ability to identify a pipeline of clinically actionable targets. Danny will be joined by industry leaders Travis Hardcastle from EditCo and Kinga Bercsenyi from Arctoris. Their expertise, combined with Danny's insights, will make this a must-attend webinar! 🗓️ Date: 18th July, 12:00 EST 📝 Register now: https://lnkd.in/ePREsEJX #Evariste #EditCo #Arctoris #AIDrugDiscovery #SyntheticLethality #TechBio #CRISPR

🚀 Evariste x NVIDIA Inception 🚀 We're thrilled to announce that Evariste has joined NVIDIA Inception, a program that supports young companies transforming industries with their technological advancements. We firmly believe that the support provided by NVIDIA will enhance the capabilities of Frobenius, our AI-enabled drug discovery platform, which excels at working with small and noisy biological datasets to identify novel blockbuster synthetic lethal targets and discover best-in-class small molecule therapeutics. As part of Inception, we will have access to NVIDIA's cutting-edge technology, expertise, and a network of like-minded teams. We are particularly excited about the support for our future exploratory research projects, which involve computationally intensive tasks. Technical assistance and access to cloud compute credits from NVIDIA will be invaluable for these projects. This development comes at an exciting time for Evariste, with promising preclinical data coming in for our lead #PKMYT1 program, as well as rapidly progressing early programs, which all serves as crucial proof-of-concept for Frobenius. If you would like to join us on our journey to transform drug discovery as a partner or an investor, we would love to hear from you! Stay tuned for more updates. 🕑 #Evariste #NVIDIAInception #AIDrugDiscovery #SyntheticLethality #TechBio

Outstanding talk by Alfie Brennan from Evariste about their #AI-enable platform #FrobeniusDiscovery for precision Oncology. Full integration with #Torx from Cresset and Collaborative Drug Discovery - CDD Vault . #CressetUGM2024 #Elixir #drugdiscovery #AIDrugDiscovery #SBDD

Congratulations to RESI Europe Innovator’s Pitch Challenge (IPC) finalist, Evariste! CEO, Anna Hercot, will pitch on June 17 in Barcelona at the Hilton Diagonal Mar Hotel. The IPC offers founders and CEOs valuable exposure during the RESI conference. Each IPC session includes a Q&A with active #earlystage #investors. Register for RESI Europe to hear 40 startups pitch their technology: www.resiconference.com #RESI #RESIEUROPE #RESIBARCELONA

We're attending the Bio International Convention this week in San Diego! ☀ Evariste always welcomes conversations with potential investors, as well as pharma/biotech partners interested in our platform and pipeline. 🔬 If you're interested in what we do, please reach out on LinkedIn or the partnering platform! 🤝 https://lnkd.in/eB4sc2TH #Evariste #BIO2024 #AIDrugDiscovery

📣 Board Announcement📣 Evariste has recently appointed two new members to our Board of Directors: Dr Xavier Jacq and Dr Olivia Rossanese. We are looking forward to working with Xavier and Olivia, as they advise Evariste's scientific strategy during a pivotal period for our company. For the full press release and more on Xavier and Olivia, see: https://lnkd.in/djYWxDiS #Evariste #AIDrugDiscovery

Earlier this week we attended BioEquity Europe in San Sebastián, where we spoke about our synthetic lethality discovery platform and programmes, as well as presenting exciting new data for PKMYT1! We are also attending the Meet2Win Oncology Partnering Convention in Bordeaux - be sure to reach out if you want to meet! #Evariste #BioEquity #Meet2Win #SyntheticLethality #AIDrugDiscovery #PKMYT1 #Oncology

We will be presenting today at the LSX World Congress! You can find us on the Showcase Biotech Startup stage at 2:00PM, where we will be presenting slides on our discovery platform, Frobenius. Feel free to reach out on LinkedIn if you are interested in hearing more and want to meet at the conference! #Evariste #AIDrugDiscovery #Frobenius #BioTech #LSX

Evariste is looking forward to attending OBN BioTrinity this week! Feel free to reach out for a chat on the partnering platform or LinkedIn 🤝 #Evariste #AIDrugDisovery #OBN #BioTrinity

☀ We are looking forward to presenting two posters at the AACR Annual Meeting 2024, held in San Diego from Apr 5-10. 🔬 CSO Alfie Brennan and Principal Scientist Daniel Miller will be showcasing some of the exciting preclinical work on our PKMYT1 inhibitor, as well as the AI-driven processes used in our identification of novel synthetic lethal gene pairs, and the discovery of best-in-class inhibitors for one of those gene pairs. 🕘 April 8, 2024, 9:00 AM - 12:30 PM Session PO.CH01.02 - Lead Identification and Optimization Abstract 1813: Discovery, biomarker validation, and pre-clinical profiling of a novel PKMYT1 inhibitor https://lnkd.in/eAQH2VH4 🕜 April 9, 2024, 1:30 PM - 5:00 PM Session PO.ET02.05 - Cancer Treatment: New Technologies Abstract 5813: AI-driven identification and validation of novel synthetic lethal gene pairs through deep mining of cancer dependency data https://lnkd.in/e9AnRtUu #Evariste #AIDrugDiscovery #MachineLearning #PrecisonMedicine #PKMYT1 #SyntheticLethality #AACR #AACR24 #Oncology